European Medicines Agency recommends granting a marketing authorization to Imatinib Actavis for adult patients with Ph+ CML in blast crisis

On 21 February 2013 the European Medicines Agency Committee for Medicinal Products for Human Use adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Imatinib Actavis intended for the treatment of: Paediatric patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myeloid leukaemia (CML) for whom bone marrow transplantation is not considered as the first line of treatment; Paediatric patients with Ph+ CML in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis; Adult patients with Ph+ CML in blast crisis. Read more here.